The Goldman Sachs Group Downgrades Ginkgo Bioworks (NYSE:DNA) to Sell
Ginkgo Bioworks (NYSE:DNA – Get Rating) was downgraded by The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research note issued on Friday, The Fly reports. They currently have a $1.25 price objective on the stock, down from their previous price objective of $3.00. The Goldman Sachs Group’s price objective […]